Your browser doesn't support javascript.
loading
From biology to personalized medicine: Recent knowledge in osteosarcoma.
Mohr, Audrey; Marques Da Costa, Maria Eugenia; Fromigue, Olivia; Audinot, Baptiste; Balde, Thierno; Droit, Robin; Abbou, Samuel; Khneisser, Pierre; Berlanga, Pablo; Perez, Esperanza; Marchais, Antonin; Gaspar, Nathalie.
Afiliação
  • Mohr A; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Marques Da Costa ME; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Fromigue O; National Institute for Health and Medical Research (INSERM) U981, Gustave Roussy Institute, Villejuif, France.
  • Audinot B; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Balde T; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Droit R; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Abbou S; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France; Department of Oncology for Children and Adolescents, Gustave Roussy Institute, Villejuif, France.
  • Khneisser P; Department of medical Biology and Pathology, Gustave Roussy Institute, Villejuif, France.
  • Berlanga P; Department of Oncology for Children and Adolescents, Gustave Roussy Institute, Villejuif, France.
  • Perez E; Department of Oncology for Children and Adolescents, Gustave Roussy Institute, Villejuif, France.
  • Marchais A; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France.
  • Gaspar N; National Institute for Health and Medical Research (INSERM) U1015, Gustave Roussy Institute, Villejuif, France; Department of Oncology for Children and Adolescents, Gustave Roussy Institute, Villejuif, France. Electronic address: nathalie.gaspar@gustaveroussy.fr.
Eur J Med Genet ; 69: 104941, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38677541
ABSTRACT
High-grade osteosarcoma is the most common paediatric bone cancer. More than one third of patients relapse and die of osteosarcoma using current chemotherapeutic and surgical strategies. To improve outcomes in osteosarcoma, two crucial challenges need to be tackled 1-the identification of hard-to-treat disease, ideally from diagnosis; 2- choosing the best combined or novel therapies to eradicate tumor cells which are resistant to current therapies leading to disease dissemination and metastasize as well as their favorable microenvironment. Genetic chaos, tumor complexity and heterogeneity render this task difficult. The development of new technologies like next generation sequencing has led to an improvement in osteosarcoma oncogenesis knownledge. This review summarizes recent biological and therapeutical advances in osteosarcoma, as well as the challenges that must be overcome in order to develop personalized medicine and new therapeutic strategies and ultimately improve patient survival.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Medicina de Precisão Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Osteossarcoma / Medicina de Precisão Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article